Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

SNWV - SANUWAVE Health, Inc. So'nggi Yangiliklar | Finranks

Home

SNWV

(SNWV)

NGM – Real vaqt narxi. Valyuta: USD

18.61

-0.24 (-1.27%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

18.61

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company.

Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results

Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results

EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 27, 2026, at 8:30 AM (ET) to present its Q4 and Full Year 2025 financial results.

Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply.

SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript

SANUWAVE Health, Inc. ( SNWV ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Morgan Frank - CEO & Chairman Peter Sorensen - CFO & Secretary Conference Call Participants Ian Cassel - Intelligent Fanatics Capital Management Llc Kyle Bauser - ROTH Capital Partners, LLC, Research Division Carl Byrnes - Northland Capital Markets, Research Division Alex Silverman - AWM Investment Company Inc Andrew Rem Presentation Operator Good day, everyone, and welcome to the SANUWAVE earnings call. [Operator Instructions] Please note, this call may be recorded.

Sanuwave Health Inc. (SNWV) Beats Q3 Earnings and Revenue Estimates

Sanuwave Health Inc. (SNWV) Beats Q3 Earnings and Revenue Estimates

Sanuwave Health Inc. (SNWV) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to a loss of $6.49 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company.

Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

09.01.2026

Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply.

Sanuwave Announces Q3 FY2025 Financial Results

Sanuwave Announces Q3 FY2025 Financial Results

Q3 2025 revenues were $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history.